NCT01256424 - Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical Neoplasia | Biotech Hunter

Enrollment

262

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

December 31, 2012

Conditions

Cervical Intraepithelial Neoplasia

Interventions

DRUG

HAL 5% with illumination

Treatment with a singe dose of 2g, HAL 5% ointment followed by photoactivation

DRUG

HAL 1% with illumination

Treatment with a singe dose of 2g, HAL 1% ointment followed by photoactivation

DRUG

HAL 0.2% with illumination

Treatment with a singe dose of 2g, HAL 0.2% ointment followed by photoactivation

DRUG

Placebo ointment without illumination

Treatment with a singe dose of 2g placebo ointment, no photoactivation

Trial Locations (2)

Haukeland University Hospital, Bergen

University Hospital Hannover, Hanover